Red light therapy
Emerging evidenceWhy it might help
Photobiomodulation with red and near-infrared light is thought to improve local microcirculation (partly via nitric oxide) and cellular energy metabolism in nerve tissue, which may ease neuropathic pain and support sensation.
What the research shows
A systematic review and additional studies suggest red/near-infrared light therapy may improve neuropathic pain, nerve conduction, and protective sensation in diabetic peripheral neuropathy, though studies are small and quality is limited. It shows promise as an adjunct but is not an established treatment.
Sources & what they found (2)
Graded claim from the Praxium evidence graph
Diabetic neuropathy has one of the deepest human PBM literatures here — 11 RCTs and 8 non-RCTs — and the results are genuinely mixed but lean positive. Yamany 2012 (850 nm, sham-controlled) showed significant pain reduction plus improved electrophysiology and foot microcirculation, and a pilot device study (Rajeswari 2024, 890 nm) reported large nerve-conduction gains; yet Swislocki 2010 found no difference in pain intensity, and Almasi 2025 saw reductions that didn't reach between-group significance. So PBM helps some patients with painful diabetic neuropathy — particularly via microcirculation and nerve conduction — but effects are inconsistent across protocols.
How strong the finding is
41 studies (26 human, incl. 11 RCTs). Yamany 2012 (RCT, 850 nm; significant pain reduction + improved electrophysiology and microcirculation), Rajeswari 2024 (pilot, 890 nm; ~100% gains in nerve-signal amplitude/conduction velocity), vs Swislocki 2010 (RCT, 870 nm; no pain-intensity difference) and Almasi 2025 (RCT, 808+905 nm, 6 J/cm2; reductions not significant between groups).
What complicates this
Substantial heterogeneity in wavelength, dose and outcomes; several rigorous RCTs are null on primary pain endpoints while others are clearly positive. Device/protocol standardization is lacking, so results don't pool cleanly.




